Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03241758
Other study ID # RadicalDoppler
Secondary ID
Status Completed
Phase N/A
First received August 3, 2017
Last updated August 4, 2017
Start date November 29, 2011
Est. completion date August 2, 2017

Study information

Verified date August 2017
Source Corporacion Parc Tauli
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A study designed to evaluate vascular changes after radical laparoscopic prostatectomy using Doppler ultrasound and the impact of such changes on erectile function and quality of life of patients. The baseline study will be compared with the study one year after surgery.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date August 2, 2017
Est. primary completion date August 2, 2017
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Male patients with prostate cancer who underwent laparoscopic radical prostatectomy

Exclusion Criteria:

- Patients who were not interested in their sexual function and refused to perform this study

- Patients who required adjuvant or salvage treatment for their prostate cancer (radiation therapy, chemotherapy or androgen deprivation therapy) during follow-up.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Doppler ultrasound
Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Corporacion Parc Tauli

Outcome

Type Measure Description Time frame Safety issue
Primary Left and right Cavernous artery diameter mm 1 year
Primary Left and right Systolic velocity cavernous artery cm/s 1 year
Primary Left and right Diastolyc velocity cavernous artery cm/s 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04964271 - Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants
Completed NCT02546908 - A Registry of Participants With Prostate Cancer in Asia
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT01683994 - Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT04838613 - Study of Diagnostic Performance of [18F]CTT1057 in BCR Phase 3
Completed NCT02364531 - A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting
Completed NCT01929655 - Japanese BAY88-8223 Monotherapy Phase II Study Phase 2
Active, not recruiting NCT05022849 - A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants Phase 1
Completed NCT03261999 - Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer Phase 3
Terminated NCT04907227 - Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China Extension Phase 3
Active, not recruiting NCT03587285 - A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer Phase 1/Phase 2
Completed NCT02217566 - Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy Phase 2
Not yet recruiting NCT04101305 - Measurement of Circulating Tumor Cells in Prostate Cancer
Active, not recruiting NCT02950064 - A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Phase 1
Withdrawn NCT02905201 - A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) N/A
Terminated NCT03066154 - Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer Phase 1
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Terminated NCT01420965 - Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer Phase 2
Completed NCT01441713 - Treatment Frequency and Satisfaction in Patients With Advanced Prostate Cancer N/A